Bevacizumab Increases Efficacy of Oxaliplatin- Based Chemotherapy for Metastatic CRC

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 14 No 8
Volume 14
Issue 8

NEW YORK-Adding bevacizumab(Avastin) to oxaliplatin [Eloxatin]/fluorouracil or to oxaliplatin/capecitabine (Xeloda) improves re

NEW YORK-Adding bevacizumab(Avastin) to oxaliplatin [Eloxatin]/fluorouracil or to oxaliplatin/capecitabine (Xeloda) improves responserates and is tolerable as firstlinetreatment of patients with metastaticcolorectal cancer (CRC), HowardS. Hochster, MD, of New YorkUniversity School of Medicine reported(abstract 3515).TREE-1 and TREE-2 StudiesThe TREE-1 study (n = 147) examinedresponses to first-line FOLFOX6(oxaliplatin, leucovorin, and bolus5-FU followed by 5-FU infusion);bFOL (oxaliplatin, leucovorin, bolus5-FU); and CapeOx (capecitabine, oxaliplatin).The TREE-2 study (n = 213)examined the effect of adding bevacizumabto each of these three regimens.The primary study endpoints wereoverall incidence of grade 3/4 toxici-ties during the first 12 weeks of studytherapy. Secondary endpoints wereefficacy (overall response rate), timeto tumor progression, overall survival,and time to treatment failure. Eligiblepatients had measurable, untreatedmetastatic CRC and a performancestatus of 0 or 1."The addition of bevacizumab inTREE-2 caused increased grade 3/4hypertension, impaired wound healing(5%), and bowel perforation (3%)in each arm," Dr. Hochster said."However, grade 3/4 toxicity with firstlinebevacizumab plus oxaliplatinbasedchemotherapy is acceptable andis less than reported for IFL (irinotecan[Camptosar], 5-FU, leucovorin)."Treatment-related toxicities are shownin Table 1.

Regimens ActiveAll the fluoropyrimidine regimenswere active, but Dr. Hochster said thatFOLFOX had the best balance of responseand toxicity. "Bevacizumab sig-nificantly improved response rates (P= .011) when added to oxaliplatin/fluoropyrimidine chemotherapy," hesaid. Confirmed overall response rateswere 63.4% with FOLFOX-B, 34.3%with bFOL-B, and 45.8% with CapeOx-B (Table 2).During an oral discussion, CharlesBlanke, MD, of Oregon CancerInstitute, Portland, said, "The additionof bevacizumab always increasedresponse, although the confidenceintervals overlapped. Bolus 5-FUappeared to be inferior to FOLFOXand probably to capecitabine-oxaliplatinin regard to time to treatmentfailure."

Related Videos
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Arvind N. Dasari, MD, MS, an expert on colorectal cancer
Related Content